Stock listing

BOATS:ASPE Aspen Neuroscience, Inc. Stock

US listing (BOATS) of Aspen Neuroscience, Inc. · home listing NASDAQ:ASPE

Follow Aspen Neuroscience, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ASPE

$12.42 USD +0.41 (+3.4%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ASPE

Past month -17.2% · daily closes, Oct 29, 2026 – Nov 20, 2026, adjusted for splits
Day range
$12.17 – $13.19 USDNov 20, 2026
Volume
130,038 sharesNov 20, 2026
Market cap
$361.2M USDAt the close on Nov 20, 2026 · price × 29.08M shares outstanding

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ASPE · Home$12.42 USD+0.41 (+3.4%)130,038$12.24$13.19$12.17$12.01Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 29, 2026 – Nov 20, 2026 · NASDAQ:ASPE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.42+0.41+3.4%$12.24$13.19$12.17130,038
$12.01+0.01+0.1%$12.00$13.37$11.76289,107
$12.00-0.23-1.9%$12.21$12.80$11.81256,815
$12.23-0.36-2.9%$12.45$12.61$12.00216,346
$12.59-1.02-7.5%$14.00$14.07$12.07173,274
$13.61-0.21-1.5%$13.95$14.42$12.62267,365
$13.82+1.01+7.9%$13.04$14.40$12.22290,515
$12.81+0.41+3.3%$12.65$13.15$12.10279,364
$12.40-0.04-0.3%$12.81$13.15$11.92215,456
$12.44+0.68+5.8%$11.52$12.72$11.47174,201
$11.76-1.00-7.8%$13.11$13.11$11.25185,200
$12.76+0.47+3.8%$11.92$12.95$11.20312,700
$12.29-0.75-5.8%$13.00$14.49$12.00639,700
$13.04-1.85-12.4%$14.65$14.65$12.63596,500
$14.89-0.11-0.7%$14.70$14.90$11.601,322,500
$15.00——$15.00$15.00$15.000
Ticker
BOATS:ASPE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

Aspen Neuroscience, Inc. on 6ix

Sector
Health care
Industry
Biotechnology

Where Aspen Neuroscience, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ASPE · Home listingNASDAQUnited StatesUSD
BOATS:ASPE · This pageBOATSUnited StatesUSD

Valuation

Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$288.8M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Aspen Neuroscience, Inc. · NASDAQ:ASPEUS$361.2MUS$288.8Mn/an/an/an/an/an/an/a
Rezolute, Inc. · NASDAQ:RZLTUS$379.2MUS$289.9Mn/an/an/a4.4×n/a0.0×1.28
Phathom Pharmaceuticals, Inc. · NASDAQ:PHATUS$378.8MUS$359.8Mn/a1.3×n/an/a−30.2%n/a1.08
Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509US$370.7MUS$380.6M4.5×2.5×4.2×2.9×53.3%0.8×n/a
Puma Biotechnology Inc · NASDAQ:PBYIUS$364.5MUS$255.9M15.3×1.1×5.8×2.5×10.3%0.0×0.88
PureTech Health PLC · LSE:PRTCUS$364.3MUS$160.3Mn/a34.4×n/a0.9×n/a0.1×n/a
Lumosa Therapeutics Co Ltd · TPEX:6535US$362.3MUS$343.1Mn/a329×n/a9.7×n/a0.0×n/a
Alector, Inc. · NASDAQ:ALECUS$347.6MUS$208.9M8.4×1.2×4.9×3.0×23.9%0.0×1.72
Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617US$347.3MUS$296.6Mn/a232×n/a4.9×−389.6%0.0×n/a
AbClon, Inc. · KRX:174900US$346.1MUS$319.1Mn/a80.9×n/a8.8×−328.3%0.0×n/a
Onconic Therapeutics, Inc. · KRX:476060US$344.4MUS$297.9M19.1×4.9×n/a5.4×29.5%0.0×n/a
Median of the othersUS$363.3MUS$297.2M11.8×4.9×4.9×4.4×10.3%0.0×1.18

Team and board

Officers

OfficerRole
Damien McDevittPresident and Chief Executive Officer
Dalen MeeterChief Financial Officer
Jeff BoernekeGeneral Counsel and Secretary
Andrés Bratt-LealSenior Vice President, Research & Development
Cindy PerettieExecutive Vice President and Global Head
Jennifer WhitakerVice President, Human Resources
Samantha MurphySenior Vice President, Corporate Development
Ana SousaChief Regulatory Officer
Caryn PetersonChief Development Officer, Gossamer
Faheem HasnainAspen Executive Chairman
Kim RaineriChief Technology Officer
Lisa Johnson-PrattSasineprocel Development Lead and Chief Commercial Officer
Revati ShreeniwasChief Medical Officer
Xiaokui ZhangChief Scientific Officer

Board

DirectorRole
Faheem HasnainAspen Executive Chairman
Damien McDevittPresident and Chief Executive Officer
Peter ThompsonDirector
Tom DanielDirector

IPO

Priced at US$15.00 a share on Oct 29, 2026.

Price
US$15.00 a share
Shares offered
9,375,000 shares of common stock
Offering size
US$140.6 million
Underwriters' option
Up to 1,406,250 more shares
Listing
ASPE on the Nasdaq Global Select Market
Underwriters
Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel, Oppenheimer & Co. · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMar 30, 2026
Filed publiclyOct 9, 2026
Amended twiceNewest Oct 26, 2026
Shares registered with an exchangeOct 29, 2026
Declared effective by the SECOct 29, 2026
Final prospectus, with the priceOct 30, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue00
Research and development41.8M35.6M
Selling, general and administrative17.1M17.4M
Operating income-59.3M-53.5M
Depreciation and amortization3.96M3.51M
EBITDA-55.3M-49.9M
Income before tax-62.1M-48.6M
Net income-62.1M-48.6M
Earnings per share, basic-2.13-1.67

Balance sheet

LineFY2025FY2024
Cash and equivalents82.1M15.2M
Short-term investments28.6M42.5M
Current assets112.4M59.6M
Total assets143.7M90.2M
Accounts payable2.64M853.0K
Current liabilities14.3M14.0M
Total liabilities360.7M247.9M
Shareholders' equity-217.1M-157.7M
Shares outstanding29.1M29.1M

Cash flow

LineFY2025FY2024
Cash from operations-52.8M-44.2M
Capital spending-9.69M-2.58M
Free cash flow-62.5M-46.7M
Cash from financing115.5M457.0K
Change in cash66.9M-23.1M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13D · Big-stake noticeNov 9, 2026Big-stake noticeSEC
4 · Change in ownershipNov 9, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 9, 2026Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 6, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 3, 2026Big-stake noticeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
All 39 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
S-8 · Registration statement for employee plansNov 2, 2026Offer documentSEC
8-K · Current reportNov 2, 2026Current reportSEC
424B4 · ProspectusOct 30, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 30, 2026Other filingsSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2026Insider tradeSEC
CERT · Exchange's certificate of listingOct 29, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 29, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 26, 2026Offer documentSEC
S-1/A · Registration statement, amendedOct 22, 2026Offer documentSEC
S-1 · Registration statementOct 9, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedJun 9, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMay 12, 2026Offer documentSEC
DRS · Draft registration statementMar 30, 2026Offer documentSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Aspen Neuroscience, Inc.’s releases

Common shares
29,078,600
Fully diluted
29,078,600

Fully diluted

LineShares
Common shares29,078,600

Share count over time

CountShares
Nov 22, 202629,078,600

Open Cap table

Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Orbimed Advisors LLC
Director, 10% owner
Buy1,000,000USD 15.00US$15MNov 2, 2026
Thompson Peter A.
Director, 10% owner
Buy1,000,000USD 15.00US$15MNov 2, 2026
ARCH Venture Partners XIV, L.P.
10% owner
Buy1,200,000USD 15.00US$18MNov 2, 2026
ARCH Venture Fund X, L.P.
10% owner
Buy66,666USD 15.00US$1000KNov 2, 2026
ARCH Venture Fund X, L.P.
10% owner
Buy1,200,000USD 15.00US$18MNov 2, 2026
ARCH Venture Fund X, L.P.
10% owner
Buy66,667USD 15.00US$1MNov 2, 2026

Big stakes

StakeStakeSharesDateFiling
ARCH Venture Fund X, L.P.12.90%3.75MNov 2, 2026Schedule 13D
Orbimed Advisors LLC12.30%3.59MNov 2, 2026Schedule 13D
FMR LLC11.20%3.25MOct 30, 2026Schedule 13G
Gilead Sciences, Inc.9.90%2.88MOct 30, 2026Schedule 13G
Qatar Investment Authority6.70%1.93MOct 30, 2026Schedule 13G
Frazier Life Sciences X, L.P.5.80%1.67MNov 2, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Faheem Hasnain
Other companies: Gossamer Bio, Inc. (Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past)
Aspen Executive Chairman · Since at least Nov 2, 2026
Peter Thompson
Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026); Sionna Therapeutics, Inc. (Director · Since at least Apr 14, 2026)
Director · Since at least Nov 2, 2026
Andrew Spaventa
Other companies: Singular Genomics Systems Inc (Chief Executive Officer, Director · May 26, 2021 – Feb 21, 2025 · Past)
Director · Since at least Nov 2, 2026
Caryn Peterson
Other companies: Gossamer Bio, Inc. (Chief Development Officer · Since at least Apr 16, 2021)
Chief Development Officer, Gossamer · Since at least Nov 5, 2026
Dalen Meeter
Other companies: Singular Genomics Systems Inc (Chief Financial Officer · May 26, 2021 – Feb 21, 2025 · Past)
Chief Financial Officer · Since at least Nov 5, 2026
Ana SousaChief Regulatory Officer · Since at least Nov 5, 2026
Andrés Bratt-LealSenior Vice President, Research & Development · Since at least Nov 5, 2026
Cindy PerettieExecutive Vice President and Global Head · Since at least Nov 4, 2026
Damien McDevittPresident and Chief Executive Officer · Since at least Nov 5, 2026
Jeff BoernekeGeneral Counsel and Secretary · Since at least Nov 4, 2026
All 17 people
PersonSeat
Jennifer WhitakerVice President, Human Resources · Since at least Nov 4, 2026
Kim RaineriChief Technology Officer · Since at least Nov 5, 2026
Lisa Johnson-PrattSasineprocel Development Lead and Chief Commercial Officer · Since at least Nov 5, 2026
Revati ShreeniwasChief Medical Officer · Since at least Nov 5, 2026
Samantha MurphySenior Vice President, Corporate Development · Since at least Nov 5, 2026
Tom DanielDirector · Since at least Nov 4, 2026
Xiaokui ZhangChief Scientific Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Aspen Neuroscience, Inc.